Topic Listing for Genelabs Technologies

Action Written Consents Activities Involve Hazardous Materials Improper Handling Employees Agents
Additional Information Adjourned Meetings
Administration Administration Amendment Termination
Adopted Board Directors 2001 Amended 2005 2007 Advancement Expenses
Aggregated Option Exercises Last Year-end Values Amendment Termination
Amendment Termination 2001 Plan Amendment Termination Plan
Amendments Amendments Bylaws
Announces Resignation Chief Financial Officer Annual Bonus Payment
Annual Bonus Plan Annual Meeting Shareholders Notice Proxy Statement Table Contents
Annual Reports Applicable Law
Appointment Procedure Approval 2007 Omnibus Stock Incentive Plan
Approval Amendment 2001 Employee Stock Purchase Plan Approval Annual Bonus Plan
Audit Committee Audit Fees Pre-approval Policies
Balance Sheet Balance Sheets
Basis Presentation Bear Cost Solicitation
Because Average Daily Trading Volume Common Stock Low Because Not Continue Qualify Listing Nasdaq Quotation System
Because Stock Volatile Value Investment Genelabs Substantially Decrease Beneficial Owner
Beneficial Ownership Reporting Compliance Board Directors
Board Directors Recommends Shareholders Vote Election Nominated Business Description
Bylaw Provisions Additional Supplemental Law Bylaws Provisions Contrary Inconsistent Law
Capital Changes Change Control Capital Gain Loss
Cash Equivalents Restricted Certain Limitations
Certain Plan Information Certain Relationships Related Transactions
Certain United States Federal Income Tax Consequences Certificates Shares
Certification Certification Chief Executive Officer Financial Pursuant 906 Sarbanes-oxley
Certification Inspection Bylaws Chairman Chief Executive Officer Compensation
Change Control Adjustments Change Control Agreements
Change Vote After Submit Proxy Changes Composition Compensation Committee
Changes Internal Control Over Financial Reporting Changes Securities Laws Regulations Increase Costs
Code Ethics Collaborations Fail
Collaborative Agreements Commitments Contingencies
Committees Common Stock
Comparison Cumulative Total Return Investment Compensation
Compensation Chairman Chief Executive Officer Scientific Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Responsibilities Authority Compensation Components
Compensation Directors Compensation Philosophy
Compensation Philosophy Review Process Compensatory Arrangements Certain Officers
Compliance Exchange Act Comprehensive Loss
Conditions Issuance Shares Limitation Sale Conference Telephone
Confidentiality Proprietary Information Consent Shareholders Meetings
Consideration Consolidated Statements Operations
Consulting Obligation Contractual Obligations
Controls Procedures Cooperation Litigation
Corporate History Headquarters Website Information Count Votes
Counterparts Critical Accounting Policies
Critical Accounting Policies Estimates Current Members Board Directors They Independent
Death Termination Employment Restrictions Transfer Departure Directors Principal Officers Election Appointment
Departure Directors Principal Officers Election Appointment Certain Departure Directors Principal Officers Election Appointment Compensatory
Descriptive Headings Designation Beneficiary
Determination Bonus Awards Development Prestara Systemic Lupus Erythematosus
Difficulties Financing Integrating Future In-licensed Acquired Drug Programs Dispute Resolution
Dissenters Rights Documents Incorporated Reference
Drug Candidates Still Early Stages Development Remain Subject Drug Development Prestara
Drug Discovery Drug Discovery Research
Each Party Drafter Earnings Per Share
Effect Amendment Election Directors
Election Qualifications Election Term Office
Eligibility Eligibility Participation
Employees Employment Contracts
Entire Agreement Equal Rights Privileges
Equity Compensation Plan Information Establishment Plan
Evaluation Disclosure Controls Procedures Exact Name Registrant Specified Charter
Executive Compensation Executive Officers
Exercise Corporate Powers Exercise Outstanding Options Warrants Dilute Shareholders Decrease Market
Exhibits Face Substantial Competition Result Others Discovering Developing Commercializing
Facilities California Located Near Earthquake Fault Disrupt Operations Facilities Located Near Earthquake Fault Disrupt Operations Adversely
Fair Value Financial Instruments Federal Income Tax Consequences
Financial Statements Exhibits Financial Terms Future Collaborative Licensing Arrangements Result Dilution
Find Voting Results Meeting Fold Detach Here
Form 10-k Form 10-q
Forward Looking Statements Forward-looking Statements
Genelabs Drug Candidate Systemic Lupus Erythematosus Not Positive Genelabs Technologies Announces Appointment Leslie Browne Matthew Pfeffer
Genelabs Technologies Inc Genelabs Technologies Inc 505 Penobscot Drive Redwood City
General General Administrative
General Administrative Expenses General Provisions
General Purpose Plan Definitions Gilead Sciences Inc
Governing Law Government Regulation
Grant Option Enrollment Held Annual Meeting Shareholders Voted Proposals Voting
Hepatitis Vaccine Impairment Long-lived Assets
Incentive Stock Options Income Taxes
Incur Significant Costs Class Action Litigation Indemnification Contracts
Indemnification Directors Officers Employees Independent Registered Public Accounting Firm
Index Index Consolidated Financial Statements
Industry Risks Inspectors Election
Instruments Writing Investigations Studies Outside Advisers
Japanese Marketing Partner Prestar Japanese Marketing Partner Prestara Not Obtain Approval Market
Lease Facilities Expires Not Continue Operations Legacy Technologies
Limitation Liability Indemnification Limitations Shares Purchased
Liquidity Capital Resources Long-term Investment
Lost Certificates Managements Annual Report Internal Control Over Financial Reporting
Manner Giving Notice Market Risks
Meetings Procedures Miscellaneous
Mutual Non-disparagement Covenant Need Not Shareholders
Need Raise Additional Capital Within Next Several Unable Net Loss Per Share
New Plan Benefits Nominating Committee
Nominees Non-exclusivity Rights
Non-operating Income Non-solicitation Non-interference
Nonassignability Nonoperating Income
Nonqualified Stock Options Not Able Obtain Maintain Sufficient Insurance Commercially Reasonable
Not Profitable Near Future Order Carry Out Business Not Resources Conduct Preclinical Development
Notice Annual Meeting Shareholders Notice Disposition
Notice Meetings Notice Special Meetings
Notices Novartis Institutes Biomedical Research
Number Number 0-19222
Offering Dates Often Did Board Directors Meet 2005
Often Did Board Directors Meet 2006 Often Did Board Directors Meet 2007
Operating Expenses Operating Lease Costs Incentives
Option Grants 2005 Options Committee Responsibilities Authority
Options Exercises Stock Vested 2006 Organization
Other Business Other Events
Other Offices Other Terms Conditions
Outside Suppliers Manufacturers Prestara Subject Regulation Including Fda Outside Supplies Manufacturers Prestar
Outside Supplies Manufacturers Prestara Subject Regulation Including Fda Overview
Part Participation
Participation Plan Parties Rely Not Perform Contractually Required Expected Able
Patents Payment Awards
Payment Purchase Price Changes Payroll Deductions Issuance Shares Payroll Deductions
Performance Measurement Comparison Performance Review
Phase Trial Prestara Lupus Place Meetings
Plan Performance Periods Objectives Power Attorney
Powers Powers Duties
Prestara Approved Marketing United States Not Orphan Drug Principal Effects Reverse Stock Split
Principal Office Private Placement Financing
Procedure Effecting Reverse Stock Split Exchange Certificates Property Equipment
Proposal Amendment 2001 Stock Option Plan Proposal Approval Adoption Genelabs Technologies Inc 2007 Omnibus
Proposal Approval Amendment Genelabs Technologies Inc 2001 Employee Proposal Increase Number Shares Available 2001 Employee Stock
Propose Actions Consideration Next Annual Meeting Shareholders Provided
Provided However Proxies
Proxy Solicited Behalf Board Directors Genelabs Technologies Inc Proxy Statement
Purchase Price Purpose
Purpose Eligibility Pursuant Securities Exchange Act 1934
Quorum Recent Accounting Pronouncement
Recent Accounting Pronouncements Recent Sales Unregistered Securities
Reclassifications Regular Meetings
Release Removal
Report Audit Committee Board Directors Report Compensation Committee Board Directors Executive
Report Independent Registered Public Accounting Firm Reports
Representations Research Development Expense
Research Development Expenses Research Development Expenses Background
Research Development Expenses Project Research Programs Early Stage Not Successfully Produce Commercial
Responsibilities Restricted Stock Deferred Performance Shares
Results Clinical Trial Prestara Genelabs Drug Candidate Systemic Results Confirmatory Clinical Trial Prestara Genelabs Drug Candidate
Results Operations Financial Condition Return Payroll Deductions
Revenue Revenue Recognition
Reverse Stock Split Review Revocation Rights
Risk Factors Risks Related Genelabs
Risks Relating Owning Stock Role Executive Officers
Rule 16b-3 Sale Diagnostic Business
Sarbanes-oxley Act 2002 Savings Plan
Secretary Securities Registered Pursuant Act Common Stock
Securities Subject Plan Separation
Severability Shareholder Approval Amendments
Shareholder Approval Effective Date Plan Shareholder Record
Shareholders Shareholders Communicate Board Directors
Shares Common Stock Directors Executive Officers Largest Shareholders Shares Held Corporation
Shares Subject 2001 Espp Signatures
Special Considerations Relating Equity Compensation 2004 Special Meetings
Statement Policy Statements Operations
Stock Appreciation Rights Stock Option Plan
Stock Options Stock Subject Plan Individual Award Limits Adjustments Change
Stock-based Compensation Subject Regulation Including Fda They Not Meet Commitments
Submission Matters Vote Security Holders Subsequent Agreement Bylaw
Summary Summary 2001 Espp
Summary Amended Restated 2001 Stock Option Plan Support Costs Other
Support Costs Other Research Development Table Contents
Tax Considerations Tax Treatment
Tax Treatment Employees 2001 Espp Tax Treatment Genelabs
Taxes Term Office Compensation
Term Plan Termination Employment
Title Class Unable Attract Retain Key Personnel
Unable Find European Marketing Partner Prestara Business Prospects Unable Obtain Patents Protect Intellectual Property Rights Others
Unfunded Status Plan United States Federal Income Tax Consequences
United States Securities Exchange Washington 20549 Unsuccessful Finding Collaboration Partner Prestara Harm Ability Recover
Vacancies Vote Required
Vote Shares Person Meeting Vote Shares Without Attending Meeting
Voting Rights Waiver
Waiver Notice Consent Watson Pharmaceuticals Inc
What Board Directors Recommendations What Constitutes Quorum
What Difference Between Holding Shares Shareholder Record Beneficial What Mean Receive Proxy Voting Instruction Card
What Purpose Annual Meeting What Shares Vote
What Standing Committees Board Directors What Vote Required Approve Each
Withdrawal Withdrawal Termination Employment
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki